Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1991 1
1993 2
1994 2
2001 1
2008 3
2009 3
2010 1
2011 2
2012 3
2013 5
2014 3
2015 5
2016 1
2017 1
2019 5
2020 5
2021 4
2022 4
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Results by year

Filters applied: . Clear all
Page 1
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, Roessner M, Gupta S, Sartor AO; TROPIC Investigators. de Bono JS, et al. Among authors: sartor ao. Lancet. 2010 Oct 2;376(9747):1147-54. doi: 10.1016/S0140-6736(10)61389-X. Lancet. 2010. PMID: 20888992 Clinical Trial.
Editorial Comment.
Prasad S, Hermanson T, Bennett CL, Sartor AO. Prasad S, et al. Among authors: sartor ao. Urology. 2015 Jul;86(1):78. doi: 10.1016/j.urology.2015.01.051. Urology. 2015. PMID: 26142588 No abstract available.
Editorial comment.
Prasad SM, Sartor AO, Bennett CL. Prasad SM, et al. Among authors: sartor ao. Urology. 2014 Jan;83(1):152-3; discussion 153. doi: 10.1016/j.urology.2013.08.085. Epub 2013 Nov 12. Urology. 2014. PMID: 24238571 No abstract available.
Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591.
Tagawa ST, Thomas C, Sartor AO, Sun M, Stangl-Kremser J, Bissassar M, Vallabhajosula S, Huicochea Castellanos S, Nauseef JT, Sternberg CN, Molina A, Ballman K, Nanus DM, Osborne JR, Bander NH. Tagawa ST, et al. Among authors: sartor ao. J Clin Oncol. 2024 Mar 1;42(7):842-851. doi: 10.1200/JCO.23.00573. Epub 2023 Nov 3. J Clin Oncol. 2024. PMID: 37922438 Clinical Trial.
Germline BLM mutations and metastatic prostate cancer.
Ledet EM, Antonarakis ES, Isaacs WB, Lotan TL, Pritchard C, Sartor AO. Ledet EM, et al. Among authors: sartor ao. Prostate. 2020 Feb;80(2):235-237. doi: 10.1002/pros.23924. Epub 2019 Nov 5. Prostate. 2020. PMID: 31816118 Free PMC article.
Longitudinal Monitoring of Circulating Tumor DNA to Assess the Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Malignancies.
Jang A, Lanka SM, Jaeger EB, Lieberman A, Huang M, Sartor AO, Mendiratta P, Brown JR, Garcia JA, Farmer T, Sudhaman S, Mahmood T, Pajak N, Calhoun M, Dutta P, ElNaggar A, Liu MC, Barata PC. Jang A, et al. Among authors: sartor ao. JCO Precis Oncol. 2023 Jul;7:e2300131. doi: 10.1200/PO.23.00131. JCO Precis Oncol. 2023. PMID: 37467457
50 results